

## Severe Asthma Update: Clinical Management and Key Considerations to Target Optimal Patient Care

### Tweetorial #4 Reference List

#### **Tweet #4:**

Novelli F, Bacci E, Latorre M, et al. Comorbidities are associated with different features of severe asthma. *Clin Mol All.* 2018;16(25). doi: 10.1186/s12948-018-0103-x

#### **Tweet #5:**

American Rhinologic Society. *Treating Chronic Rhinosinusitis with Nasal Polyps*. American College of Allergy, Asthma & Immunology; 2020. Accessed October 19, 2020. <https://www.american-rhinologic.org/assets/images/newsletter/Fall2020/CRSwNP%20SDM%20Paper%20Tool%20-%20FINAL.pdf>

#### **Tweet #7:**

Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. *Allergy.* 2019;74(12):2312-2319. doi: 10.1111/all.13875

#### **Tweet #9:**

Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet.* 2019;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1

#### **Tweet #10:**

Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J All Clin Immunol.* 2020;146(3):595-605.